Eli Lilly’s Foundayo (Orforglipron) Demonstrates Significant Weight Loss Across All Menopausal Stages – Addresses Critical Gap in Women’s Metabolic Health

Eli Lilly and Company (NYSE: LLY) announced groundbreaking results from the ATTAIN-1 and ATTAIN-2 clinical trials demonstrating that Foundayo (orforglipron), its oral GLP-1 receptor agonist, achieved substantial weight loss across all stages of menopause in women with obesity or overweight. The data addresses a major unmet need, as menopause-related hormonal changes significantly accelerate abdominal fat accumulation and impair weight loss efforts in over 1.2 billion women globally.

Clinical Trial Results by Menopausal Status

ATTAIN-1 Study (Obesity/Overweight Population)

ATTAIN-2 Study (Type 2 Diabetes Population)

Secondary Endpoints & Body Composition

• Waist Circumference Reduction: Up to 4.9 inches (12.5 cm) in ATTAIN-1 and 4.3 inches (11.0 cm) in ATTAIN-2 at week 72
• Abdominal Fat Targeting: Clinically significant reduction in visceral adiposity, addressing menopause-specific fat distribution patterns
• Metabolic Improvements: Enhanced insulin sensitivity and glycemic control in diabetic cohort
• Durability: Sustained weight loss maintained through 72-week treatment period

Market Opportunity & Strategic Significance

• Addressable Population: 1.2 billion women globally experiencing menopause-related metabolic challenges
• Competitive Differentiation: First oral GLP-1 specifically demonstrating efficacy across all menopausal stages
• Therapeutic Gap: Current weight management therapies show reduced efficacy in postmenopausal women due to hormonal changes
• Commercial Potential: Premium positioning in women’s health segment of $100B+ GLP-1 market
• Regulatory Timeline: NDA submission expected Q3 2026 with potential approval in H1 2027

Scientific Innovation & Mechanism

• Oral Bioavailability: Orforglipron represents next-generation oral GLP-1 with improved pharmacokinetic profile
• Hormonal Interaction: Maintains efficacy despite estrogen decline and associated metabolic changes during menopause
• Central vs. Peripheral Effects: Dual action on appetite regulation and peripheral metabolism overcomes menopausal resistance
• Safety Profile: Favorable gastrointestinal tolerability compared to injectable GLP-1 analogs

Competitive Landscape Context

Forward‑Looking Statements
This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial expectations for Foundayo. Actual results may differ due to final regulatory decisions, competitive dynamics, market adoption rates, and evolving treatment guidelines.-Fineline Info & Tech